South Korea debates reimbursement for hair loss treatments

Seoul – 01.07.2026: In South Korea, the debate over whether to include therapies for hair loss in the benefits catalogue of the state health insurance system has intensified. The Ministry of Health had planned a public roundtable for the end of June, but cancelled it at the last minute. Officially, the reason given was the need for further technical consultations. Politically, the issue therefore remains on the agenda, but a final decision has yet to be made.
The origin of the debate is an initiative by President Lee Jae-myung. He argues that alopecia is not merely a cosmetic problem, but can have significant psychological and professional consequences. At the same time, authorities in June examined whether to expand reimbursement coverage for certain selected medicines. An adjustment to the guidelines for the oral drug baricitinib (marketed, among others, as Olumiant) was due to take effect on 1 July and primarily concern patients with severe forms of alopecia, some of autoimmune origin.
Criticism was quick to follow. Patient organisations for rare and serious diseases, some sections of the medical profession and civic initiatives warned against an expansion that would dilute the core mandate of social insurance. In their view, scarce resources should be directed primarily towards life-threatening or particularly costly illnesses. The Korea Patient Organizations Alliance described it as a hasty political move with potentially high long-term costs for the system.
Supporters counter that hair loss demonstrably reduces quality of life and may be accompanied by depression, anxiety disorders and social stigma. In addition, some forms of alopecia in South Korea are already reimbursed under strict indications. According to experts, an orderly extension could establish clear criteria, for example to distinguish between milder forms and severe clinical conditions, thereby preventing abuse. Demand is high: alongside medicines, a market for transplants and cosmetic services is flourishing, the costs of which have so far been borne almost entirely by private individuals.
Behind the dispute lies a broader structural problem. National health insurance is under pressure due to an ageing population and rising healthcare costs. Any extension of the benefits catalogue must therefore be assessed in terms of financial stability, scientific evidence and equity issues. The ministry emphasises that it will continue to examine clinical effectiveness, patient benefit and budgetary impact. Observers anticipate a multi-stage process that could clarify guidelines and indications.
Politically, the issue could have lasting effects. The question of which illnesses are reimbursable by the state touches on fundamental debates about solidarity, priority-setting and transparency in decision-making processes. Regardless of the timetable for baricitinib, the case signals that health policy in South Korea is increasingly being measured against society’s expectations.